Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2DB5T
|
|||
| Drug Name |
TBX-3400
|
|||
| Drug Type |
Cell therapy
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 1 | [1] | |
| Company |
Taiga Biotechnologies
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03385486) Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.